The goal of the CALQUENCE Patient Savings Program is to assist eligible patients with their out-of-pocket costs for CALQUENCE® (acalabrutinib).
Most eligible patients will pay $0 per month and may have access to up to $26,000 per year to assist with CALQUENCE out-of-pocket costs. There are no income requirements to participate in the program.
Talk to your doctor or pharmacist, who can help you enroll in the program and file claims on your behalf. For additional information, please visit www.astrazenecaspecialtysavings.com or call Access 360 at 1-844-ASK-A360 (1-844-275-2360).
Patients are ineligible if prescriptions are paid by any state or other federally funded programs, including, but not limited to, Medicare Part B, Medicare Part D, Medicaid, Medigap, VA or TRICARE, or where prohibited by law. Eligibility rules apply. Additional restrictions may apply.
The CALQUENCE Patient Savings Program covers the cost of the drug only, and does not cover costs for office visits, or any other associated costs.
Offer is invalid for claims and transactions more than 120 days from the date of service.
Affordability Brochure Download now
These are not all the possible side effects of CALQUENCE. Call your doctor for medical advice about side effects.
You may report side effects related to AstraZeneca products by clicking here.
What is CALQUENCE?
CALQUENCE is a prescription medicine used to treat adults with mantle cell lymphoma (MCL) who have received at least one prior treatment for their cancer.
It is not known if CALQUENCE is safe and effective in children.